Novartis Secures Pluvicto mHSPC Approval, Now Faces Sobering Cost-Effectiveness Battle

FDA Approves Pluvicto for PSMA+ mHSPC

Novartis announced the US FDA approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) in combination with an androgen receptor pathway inhibitor (ARPI) for PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC). This approval, based on the Phase III PSMAddition trial, showed Pluvicto reduced the risk of progression or death by 28% at primary analysis and 33% at an updated analysis, with a positive overall survival trend (HR=0.80). This expands Pluvicto's use across all stages of PSMA-positive metastatic prostate cancer, nearly doubling the eligible patient population, building on its established use in mCRPC.

• The FDA approval of Pluvicto for PSMA-positive mHSPC, in combination with an ARPI, significantly expands its utility. This marks a shift towards earlier, targeted intervention in prostate cancer, nearly doubling the eligible patient population and building on its established use in mCRPC. This approval is seen as a major step in redefining prostate cancer care by offering a precision option from the initial metastatic diagnosis.
• The approval is supported by data from the Phase III PSMAddition trial. Pluvicto, when combined with standard of care (ARPI + ADT), demonstrated a significant reduction in the risk of progression or death. At primary analysis, this reduction was 28% (HR 0.72), which further improved to 33% (HR 0.67) in a subsequent updated analysis. The trial also showed a positive overall survival trend (HR=0.80) as data mature.
• Pluvicto's safety profile and tolerability in PSMAddition were consistent with previous trials (PSMAfore and VISION). While grade ≥3 adverse events were slightly higher in the Pluvicto arm (50.7% vs 43.0%), health-related quality of life was maintained. The approval addresses a significant unmet need in mHSPC, where about half of men progress within 20 months despite current treatments, emphasizing the importance of earlier, differentiated approaches.

Pluvicto's Impact on the Evolving mHSPC Landscape

The treatment landscape for metastatic hormone-sensitive prostate cancer (mHSPC) has been significantly influenced by advancements in prostate-specific membrane antigen (PSMA)-targeted diagnostics. The adoption of PSMA-PET/CT imaging, which is superior to conventional CT and bone scans for detecting metastatic disease, has improved staging accuracy and enabled more personalized treatment planning. Beyond diagnostics, PSMA-PET/CT has also demonstrated prognostic value. In a study of patients with metachronous mHSPC, a high maximum standardized uptake value (SUVmax) on PSMA-PET/CT was found to be a significant prognostic factor, predicting a greater PSA response in patients treated with androgen deprivation therapy (ADT) plus a second-generation androgen receptor signaling inhibitor (ARSI) compared to those receiving ADT with a first-generation antiandrogen.

Building on the success of PSMA-targeted agents in the metastatic castration-resistant setting (mCRPC), the focus has shifted toward evaluating these therapies in earlier disease stages, including mHSPC. While high-quality evidence from controlled trials for PSMA-targeted radioligand therapy (RLT) specifically in mHSPC is still forthcoming, numerous clinical trials are currently underway. Emerging data from adjacent populations show promise; for instance, second-line PSMA-guided metastasis-directed therapy (MDT) in patients with oligorecurrent prostate cancer resulted in significantly higher metastasis-free and CRPC-free survival compared to conventional approaches. The successful translation of RLT into the mHSPC setting will depend on resolving key parameters, including optimal dosing, dosimetry, and long-term safety, as well as validating prognostic biomarkers such as circulating tumor DNA (ctDNA) and PSMA-positive tumor volume for this specific patient population.

Key Efficacy and Safety Data from PSMAddition

Recent clinical trials are actively investigating the role of PSMA-targeted therapies in metastatic hormone-sensitive prostate cancer (mHSPC), shifting these potent treatments into earlier disease settings. The Phase 3 PSMAddition trial provides key evidence, demonstrating that adding radioligand therapy to the standard of care can significantly improve outcomes for this patient population.

• PSMAddition Trial: This Phase 3 study showed that adding first-line [177Lu]Lu-PSMA-617 to an androgen receptor pathway inhibitor (ARPI) and androgen deprivation therapy (ADT) significantly improved radiographic progression-free survival compared to the ARPI and ADT doublet alone. Common adverse events associated with the addition of [177Lu]Lu-PSMA-617 included dry mouth, fatigue, gastrointestinal issues, and low blood counts.

• BULLSEYE Trial: In this Phase 2 trial for oligometastatic HSPC, patients receiving [177Lu]Lu-PSMA-617 had a median progression-free survival of 25 months, versus 5 months for the control group receiving deferred ADT. Only 7% of patients in the intervention arm experienced disease progression within the first 30 weeks, compared to 93% in the control arm, with a safety profile of mostly low-grade, manageable adverse events.

• CHAMPION Trial: This Phase 2 study evaluated a response-adapted strategy involving apalutamide and ADT, followed by consolidative therapy (e.g., radical prostatectomy or stereotactic body radiotherapy) targeting residual PSMA-positive lesions. The approach was highly effective, with 95.8% of patients achieving an undetectable PSA level (≤0.2 ng/mL) after six cycles of apalutamide, and a manageable adverse event profile where grade ≥3 rash was the only notable toxicity (4.2% of patients).

• Real-World Prognostic Data: A retrospective study stratified mHSPC patients by PSMA PET/CT findings and found that those with PSMA-positive but CT-negative (PSMA+/CT-) disease had a significantly better prognosis, with longer PSA progression-free and castration resistance-free survival. The study also suggested that in this PSMA+/CT- subgroup, intensification with an ARSI did not significantly improve survival over ADT monotherapy, highlighting a need for prospective validation.

• REDOOM Trial Design: Future research, exemplified by the REDOOM trial protocol, is exploring neoadjuvant strategies in oligometastatic HSPC. This study will assess rezvilutamide plus ADT (with or without docetaxel) prior to cytoreductive radical prostatectomy, using pathological complete response as the primary endpoint to measure treatment efficacy at the microscopic level before surgery.

Why New Precision Options are Needed in mHSPC

Current management of PSMA-positive mHSPC is complicated by disease heterogeneity, an evolving therapeutic landscape, and a lack of validated tools to guide treatment selection and sequencing. While treatment intensification strategies have improved outcomes, several gaps remain before precision approaches can be fully optimized for this population.

• Molecular and clinical heterogeneity: mHSPC is a biologically diverse disease, and differences in PSMA/CT status (e.g., PSMA-positive/CT-negative vs. PSMA-positive/CT-positive) are associated with distinct prognoses — including differential risk of PSA progression and castration resistance — yet these distinctions are not consistently incorporated into treatment algorithms.

• Absence of validated predictive biomarkers: As PARP inhibitors and PSMA-targeted therapies enter clinical practice alongside established options (docetaxel, ARPIs), clinicians face a continued dilemma in selecting and sequencing treatments without biomarkers validated for this purpose; evidence supporting biomarker-driven decisions currently relies largely on small retrospective cohorts.

• Limited trial infrastructure to guide sequencing: Landmark trials establishing efficacy of current therapies used placebo or minimally effective control arms, and there remains a paucity of prospective trials directly comparing treatment sequences or head-to-head regimens, alongside substantial overlap in trial eligibility criteria.

• Uncertain benefit of intensification in favorable-risk subgroups: In PSMA-positive/CT-negative disease, ARSI intensification has not shown a statistically significant improvement in castration resistance-free survival over ADT monotherapy in retrospective analysis, underscoring the need for prospective validation before intensification strategies are broadly applied to this subgroup.

• Toxicity and delivery constraints of radioligand therapy: PSMA-targeted radioligand therapy (e.g., ¹⁷⁷Lu-PSMA-617) is not curative, and its activity is limited by kidney and bone marrow toxicity, as well as off-target effects such as PSMA expression in lacrimal glands leading to dry eye and blepharitis; extensive further study is needed to confirm safety and stability before broader use in earlier disease states.

• Need for deeper biological understanding: Improved characterization of tumor heterogeneity, clonal evolution, and metastatic homing is required to inform future strategies for both local and systemic disease control, as well as to enable more personalized monitoring and treatment intensification/deintensification decisions.

Expanding Pluvicto's Reach Beyond mHSPC

Beyond PSMA-positive mHSPC, lutetium Lu 177 vipivotide tetraxetan (¹⁷⁷Lu-PSMA-617) has an established and expanding footprint in metastatic castration-resistant prostate cancer (mCRPC), spanning post-taxane, taxane-naive, and third-line settings. Ongoing and completed trials are also evaluating combination strategies with AR pathway inhibitors, PARP inhibitors, and immunotherapies, alongside real-world comparative analyses, to define its optimal positioning across the disease continuum.

Collectively, these programs indicate a strategic shift toward deploying ¹⁷⁷Lu-PSMA-617 earlier in the mCRPC treatment sequence and in combination regimens, moving beyond its current late-line, heavily pretreated indication toward potential first-line or combined therapeutic roles.